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Complement activation is an important component of the innate immune response against viral infection
and also shapes adaptive immune responses. Despite compelling evidence that complement activation en-
hances T cell and antibody (Ab) responses during viral infection, it is unknown whether inhibition of com-
plement by pathogens alters these responses. Vaccinia virus (VACV) modulates complement activation by
encoding a complement regulatory protein called the vaccinia virus complement control protein (VCP).
Although VCP has been described as a virulence factor, the mechanisms by which VCP enhances VACV
pathogenesis have not been fully defined. Since complement is necessary for optimal adaptive immune
responses to several viruses, we hypothesized that VCP contributes to pathogenesis by modulating anti-VACV
T cell and Ab responses. In this study, we used an intradermal model of VACV infection to compare
pathogenesis of wild-type virus (vv-VCPwt) and a virus lacking VCP (vv-VCPko). vv-VCPko formed smaller
lesions in wild-type mice but not in complement-deficient mice. Attenuation of vv-VCPko correlated with
increased accumulation of T cells at the site of infection, enhanced neutralizing antibody responses, and
reduced viral titers. Importantly, depleting CD8 T cells together with CD4 T cells, which also eliminated T
helper cell-dependent Ab responses, restored vv-VCPko to wild-type levels of virulence. These results suggest
that VCP contributes to virulence by dampening both antibody and T cell responses. This work provides insight
into how modulation of complement by poxviruses contributes to virulence and demonstrates that a pathogen-
encoded complement regulatory protein can modulate adaptive immunity.
Complement is a critical component of the innate immune
response and contributes to defenses against multiple viral
pathogens, including poxviruses (5, 40). In response to the
antiviral effects of complement, viruses have developed strat-
egies to evade complement activation (4, 9, 27, 35). Vaccinia
virus (VACV), the prototypic member of the poxvirus family,
encodes a protein called the vaccinia virus complement control
protein (VCP), which limits complement activation by inhibit-
ing several early steps of the complement cascade (25, 26, 36).
VCP limits complement activation by dissociating the C3 and
C5 convertases, which are necessary to initiate and sustain
activation of the cascade, and by acting as a cofactor for the
serine protease factor I to promote degradation and inactiva-
tion of C3b and C4b (31, 36, 42, 45, 46, 48). In vitro, VCP has
been shown to protect viral particles from complement-medi-
ated neutralization (19, 20) and prevent complement-depen-
dent lysis of infected cells (16).
Complement activation by the classical, lectin, and alterna-
tive pathways results in production of fragments with distinct
antiviral properties (5, 58, 59). These include the proinflam-
matory peptides C3a and C5a, as well as C3b and C4b, which
can mediate direct virus neutralization by opsonizing viral par-
ticles. Production of C3b also leads to downstream activation
of C5 and formation of the membrane attack complex, which
lyses infected cells and enveloped viral particles (5). Comple-
ment activation can also contribute to defense against viral
infection by enhancing adaptive antibody (Ab) and T cell re-
sponses. Complement has been shown to enhance Ab re-
sponses to several viruses, including herpes simplex virus
(HSV) (7, 14, 15, 55, 56), vesicular stomatitis virus (VSV) (44),
and West Nile virus (WNV) (37, 38). Recently, it has become
clear that complement is also important for eliciting optimal T
cell responses to several viral pathogens (10, 24, 37, 50). Dur-
ing viral infection, complement-deficient mice exhibit reduced
expansion and accumulation of CD4 and CD8 T cells fol-
lowing infection with influenza virus (24), WNV (37), or lym-
phocytic choriomengitis virus (LCMV) (50). Consistent with
these findings, deficiency in the mammalian complement reg-
ulatory protein Daf-1 results in increased complement activa-
tion, which leads to enhanced CD8 T cell responses following
infection with LCMV (10). Although the mechanisms by which
complement enhances T cell-mediated immune responses
have not been fully elucidated, it is clear that complement
activation is important for generation of protective T cell-
mediated immune responses.
Despite compelling evidence that complement activation en-
hances Ab and T cell responses (7, 10, 14, 15, 23, 24, 37, 44, 50,
55, 56), it is unknown whether inhibition of complement by
pathogens can also limit adaptive immune responses. VCP has
been characterized as a virulence factor (20), but the mecha-
nisms by which it contributes to the pathogenesis of VACV in
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vivo have not been fully defined. VACV infection can be
cleared by either Th-dependent Ab responses or CD8 T cell
responses (1, 60). Since complement has been shown to en-
hance antiviral Ab and T cell responses, we hypothesized that
VCP may contribute to pathogenesis by modulating anti-
VACV Ab and T cell responses in a complement-dependent
manner. In this study, we used an intradermal model of VACV
infection to compare pathogenesis and immune responses gen-
erated by wild type virus (vv-VCPwt) and a virus specifically
lacking VCP (vv-VCPko). Infection with vv-VCPko resulted in
smaller lesions than vv-VCPwt and was associated with in-
creased numbers of CD8 and CD4 T cells at the site of
infection as well as enhanced helper T cell (Th)-dependent
neutralizing Ab responses. However, in mice depleted of both
CD8 and CD4 T cells, vv-VCPko was no longer attenuated,
demonstrating that the ability of VCP to suppress adaptive
immune responses contributes to its role in pathogenesis. Im-
portantly, vv-VCPwt and vv-VCPko were equally pathogenic in
C3/ mice, indicating that VCP contributes to VACV patho-
genesis in a complement-dependent manner.
MATERIALS AND METHODS
Mice. C3/ mice on the C57BL/6 (B6) background were generously provided
by J. D. Lambris (University of Pennsylvania) and were bred at the University of
Pennsylvania. Age-matched wild-type C57BL/6 mice were used as controls (The
Jackson Laboratory, Bar Harbor, ME). All experiments were performed with 6-
to 9-week-old female mice, and all mice were maintained under specific-patho-
gen-free conditions. Experiments were conducted in accordance with the guide-
lines of the University of Pennsylvania Institutional Animal Care and Use
Committee.
Viruses and infections. The construction of vv-VCPwt and vv-VCPko viruses
has been described previously (16). These viruses are marker-free recombinants
that were generated from the parental virus vSIGK-3, in which the VCP open
reading frame was disrupted by insertion of a guanine phosphoribosyltransferase
expression cassette (20, 25). All in vivo infections used virus that was purified
twice through a 36% sucrose cushion (10 ml) at 24,000  g for 60 min. For ear
pinna infections, 2  104 PFU of the indicated virus suspended in 10 l of
phosphate-buffered saline (PBS) were injected into the dorsal sides of the right
and left ear pinnae by using a 29-gauge insulin syringe (Becton Dickinson).
Lesion diameters were measured using digital calipers (Fisher Scientific). For
intranasal (i.n.) challenge, mice were infected with 1  107 PFU of VACV strain
WR suspended in 20 l of PBS. Challenged mice were monitored daily for
weight loss. Animals that lost 30% of their body weight were humanely sacrificed.
In some studies, T cells were depleted by injecting mice intraperitoneally (i.p.) on
day 2 and 1 before infection and on day 3 after infection with 0.2 mg/mouse
anti-CD4 Ab (clone GK1.5; BioXcell) and/or 0.3 mg/mouse anti-CD8 Ab (clone
2.43) suspended in a total volume of 200 l PBS. Undepleted control mice were
injected with 200 l PBS. The efficiency of T cell depletion was checked on day
8 postinfection in submaxillary lymph nodes. Lymph nodes were harvested,
teased into a single-cell suspension, and passed through a 40-m cell strainer.
Cells were stained with anti-CD4 peridinin chlorophyll protein (clone RM4.5;
BD PharMingen) and anti-CD8–fluorescein isothiocyanate (FITC) conjugate
(clone 53-6.7; Biolegend) as described below and collected on a FACSCalibur
apparatus. Treatment of mice resulted in depletion of95% of CD4, CD8, or
both subsets of T cells.
Virus growth curves. To assess the abilities of vv-VCPwt and vv-VCPko to
replicate in vitro, we performed single-step and multistep growth curves. Con-
fluent monolayers of BSC-1 cells were infected with 5 PFU/cell of the indicated
virus diluted in minimal essential medium (MEM) containing 2.5% fetal bovine
serum (FBS; medium referred to as 2.5% MEM) for single-step growth curves or
with 0.05 PFU/cell for multistep growth curves. Two hours postinfection, the
inoculum was replaced with fresh medium. At the indicated time points, cells
were washed and harvested in 1 ml fresh 2.5% MEM. Cells were then freeze-
thawed three times and sonicated to release virus, and titers were determined as
described below.
Determination of viral titers in the ear. To determine viral titers, infected ears
were removed after euthanizing mice, washed in 70% ethanol, allowed to dry,
and then placed in 2.5% MEM. Ears were minced, freeze-thawed three times,
and sonicated to release the virus. Serial 10-fold dilutions of supernatant from
processed ears were performed in 2.5% MEM. Dilutions were plated on mono-
layers of BSC-1 cells and incubated at 37°C for 2 h. Medium was then removed,
and the cells overlaid with 2.5% MEM–1% carboxymethylcellulose (CMC). The
plates were incubated for 2 days at 37°C, and then plaques were visualized by
crystal violet staining and counted.
Ab ELISAs and plaque reduction neutralization assay. B6 or C3/ mice
infected with vv-VCPwt or vv-VCPko or uninfected naive mice were bled at
various times after infection. For enzyme-linked immunosorbent assay (ELISA)
experiments, 96-well Maxisorp Immuno plates (Nunc) were coated overnight at
4°C using whole-cell vaccinia virus-infected cell lysates in bicarbonate coating
buffer as previously described (17, 57). After washes, plates were blocked in
blocking buffer (PBS–1% BSA–0.05% Tween) for 1 h at room temperature
(RT). Serial 2-fold dilutions of sera from B6 mice in blocking buffer were added
in duplicate, and plates were incubated overnight at 4°C. Bound IgG or IgM was
detected with either horseradish peroxidase-conjugated rabbit anti-mouse IgG
H&L (Abcam) at 1:4,000 or a rat anti-IgM monoclonal antibody (BD Pharmin-
gen) at 1:1,000. The plates with secondary antibodies were incubated for 1 h at
37°C, washed, and incubated with 2,2-azinobis(3-ethylbenzthiazolinesulfonic
acid) substrate for 20 min at RT, and absorbance was measured using an ELISA
reader at 405 nm. For plaque reduction neutralization assays, heat-inactivated
serum from individual mice in each group (n  4) was diluted 1:100 and com-
bined with 100 PFU of the mature virus (MV) form of wild-type VACV. Virus
and sera were incubated together for 2 h at 37°C and then added to confluent
monolayers of BSC-1 cells in 12-well plates. Virus was incubated with cells at
37°C for 2 h and then overlaid with 2.5% MEM containing 1% CMC. Forty-eight
hours later, plaques were visualized by staining with crystal violet and counted.
Cell isolation and flow cytometry. To isolate cells from the ears, amputated
ears were washed in 70% ethanol and allowed to dry. Dorsal and ventral sheets
were separated using forceps and incubated dermal side down on Dulbecco’s
modified Eagle’s medium (DMEM) containing 0.5 mg/ml collagenase (Dispase;
Roche) for 45 min at 37°C. Ears were then processed for 4 min in a Medimachine
(BD Systems) using a 40-m Medicon filter (BD Systems). Cells were recovered
from the Medicon in complete tissue culture medium (CTCM; DMEM, 10%
heat-inactivated FBS [HyClone], 25 mM HEPES, 5  105 M 2-mercaptoeth-
anol, 2 mM glutamine, and 1 antibiotic/antimycotic [Invitrogen]) by using a
10-ml sliptip syringe and passed through a 40-m cell strainer. Cells were then
pelleted, resuspended in 0.01 M Tris-HCl (pH 7.4) containing 0.84% (wt/vol)
NH4Cl to lyse red blood cells, and incubated for 5 min at room temperature.
Cells were pelleted, resuspended in CTCM, and counted on a hemacytometer.
Live cells were identified by trypan blue exclusion.
The frequencies of T cells in the ear were determined by flow cytometry. Cells
were washed once with PBS and stained with Aqua Blue LIVE/DEAD fixable
viability dye (Invitrogen) for 10 min on ice. Fc Block (BD Biosciences) was then
added at 10 g/ml and incubated for an additional 5 min on ice. For phenotypic
analysis of T cells, cells were surface stained with the following Ab conjugates
diluted in fluorescence-activated cell sorting (FACS) buffer (PBS, 1% FBS, 5
mM EDTA, 0.04% sodium azide) for 30 min on ice: anti-CD3 (with allophyco-
cyanin [APC] or APC-Cy7; Biolegend), anti-CD4 (with phycoerythrin [PE]-
Cy5.5; Caltag), anti-CD8 (Pacific Blue or efluor450; eBioscience), anti-CD45
(APC; Biolegend), anti-CD11b (PE-Cy5; Biolegend). Cells were then washed
twice in FACS buffer and fixed with 1% paraformaldehyde. Fluorescence-minus-
one (FMO) controls were also included and were used for gating. Antibody
capture beads were used to prepare compensation tubes for each Ab. Samples
were collected on an LSR II apparatus (BD Immunocytometry Systems)
equipped with blue (488 nm), red (633 nm), violet (407 nm), and green (532 nm)
lasers and analyzed using FlowJo software (TreeStar, Ashland, OR). T cells were
identified by gating on single, live, CD45, CD3, CD11b cells. CD4 and CD8
T cells were then identified as CD4 CD8 and CD8 CD4. The total numbers
of CD3 CD11b, CD4, and CD8 cells were determined by calculating the
frequencies of these cells in the total cell population and multiplying each
frequency by the total number of cells isolated from infected ears.
Analysis of anti-VACV T cell responses. Submaxillary draining lymph nodes
(dLN) were isolated from mice infected with either vv-VCPko or vv-VCPwt and
teased into single-cell suspensions. Cells were then resuspended in 0.01 M Tris-
HCl (pH 7.4) containing 0.84% (wt/vol) NH4Cl to lyse red blood cells, washed,
and counted. To analyze VACV-specific gamma interferon (IFN-) responses,
1  106 cells were plated in 96-well plates and stimulated with the VACV
immunodominant peptide B820–27 (TSYKFESV; Genscript) (51) for 6 h in the
presence of Brefeldin A (BD GolgiPlug). Following stimulation, cells were
washed once in FACS buffer and incubated with Fc Block. Cells were then
surface stained with FITC-conjugated anti-CD8 Ab (BD Biosciences), fixed,
permeabilized with CytoFix/CytoPerm (BD Biosciences), stained intracellularly
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with Alexa-647-conjugated anti-IFN- Ab (BD Biosciences), and acquired using
a FACSCalibur instrument (Becton Dickinson).
CD8 T cell responses were also analyzed by surface staining cells with B820–27
peptide-major histocompatibility complex (MHC) tetramer complexes (gener-
ously provided by E. John Wherry, Wistar Institute, Philadelphia, PA). Biotin-
ylated MHC H-2Kb–peptide complexes were made as previously described (43)
and were tetramerized using APC-conjugated streptavidin (Molecular Probes).
Draining lymph node cells were isolated and stained directly ex vivo. Cells were
incubated with Fc Block (BD Bioscience) and Aqua Blue viability dye (Invitro-
gen) as described above and surface stained with B820-27 tetramer, FITC-conju-
gated anti-CD62L, Pacific Blue-conjugated anti-CD8, Alexa-700-conjgated anti-
CD3, PE–anti-CD44, and PE-Cy5.5–anti-CD4. Samples were collected on an
LSRII instrument as described above.
Statistics. Statistical significance was determined using an unpaired Student’s
t test, and P values of less than 0.05 were considered significant.
RESULTS
Deletion of VCP does not affect viral replication in vitro.
VCP has previously been shown to be dispensable for viral
replication in vitro but to contribute to pathogenesis in vivo (20,
25). To confirm that construction of vv-VCPwt and vv-VCPko
did not affect the replication capacities of these viruses, we
performed single-step and multistep growth curves to assess
the ability of these viruses to replicate and spread in vitro.
vv-VCPwt and vv-VCPko replicated equally well in both of
these assays (Fig. 1), demonstrating that deletion or rescue of
VCP in our viruses did not affect in vitro viral replication
VCP contributes to pathogenesis. To assess whether VCP
affects pathogenesis of VACV, we used an intradermal route
of infection that closely resembles human VACV vaccination.
Thus, although VACV is not a natural pathogen of mice, this
route of infection and the dose of virus used mimics the use of
this virus as a vaccine. B6 mice were infected intradermally
(i.d.) in the ear pinna with 2  104 PFU of vv-VCPwt or
vv-VCPko, and lesion sizes were measured over time. Lesion
development occurred with similar kinetics in mice infected
with either vv-VCPwt or vv-VCPko and peaked at day 10
postinfection. However, throughout the course of infection,
mice infected with vv-VCPwt had significantly (P 	 0.01)
larger lesions than mice infected with vv-VCPko (e.g., 5.83 mm
versus 3.66 mm on day 10) (Fig. 2A and C).
To determine if VCP’s role in pathogenesis is dependent on
complement, C3/ mice were infected in the ear pinna with
vv-VCPwt or vv-VCPko, and lesion sizes were monitored. In
contrast to B6 mice, in which vv-VCPko formed smaller lesions
than vv-VCPwt, lesions formed by vv-VCPwt and vv-VCPko in
C3/ mice were similar at all time points. Since both viruses
formed lesions of similar size in mice lacking a central com-
ponent of the complement cascade, this indicates that VCP
contributes to pathogenesis in a complement-dependent fash-
ion (Fig. 2B and D). Although vv-VCPwt and vv-VCPko
formed lesions of similar sizes in C3/ mice, development of
lesions in these mice was associated with dermal erosion be-
ginning on day 8 postinfection (Fig. 2D), which suggests that
complete complement deficiency results in some immunopa-
thology after VACV infection.
Expression of VCP leads to increased viral titers. To begin
to understand how VCP’s ability to inhibit complement con-
tributes to the difference in pathogenesis of vv-VCPwt and
vv-VCPko, we examined viral titers in the ears after infection.
Titers for ears from wild-type B6 mice infected with vv-VCPwt
or vv-VCPko were determined on days 4, 6, 8, and 12 postin-
fection. There was no difference in viral titer at day 4 (Fig. 3)
or day 6 (data not shown), suggesting that complement activa-
tion does not contribute to early control of viral replication in
this model of poxvirus infection. However, at days 8 and 12, B6
mice infected with vv-VCPko had significantly lower titers of
virus in the ear (Fig. 3A), indicating that these mice control
viral replication faster than those infected with vv-VCPwt.
In contrast to B6 mice, viral titers in C3/ mice were
similar at all time points following infection with vv-VCPwt
and vv-VCPko (Fig. 3B). While titers in B6 mice infected with
vv-VCPwt decreased between day 8 and day 12, titers in C3/
remained high (Fig. 3), suggesting that these mice have a
reduced ability to control viral replication.
FIG. 1. Deleting VCP does not affect viral replication or spread in
vitro. BSC-1 cells were infected with 5 PFU/cell (A) or 0.05 PFU/cell
(B). The amount of virus produced was determined based on virus
titers in infected cells at the indicated times after infection.
FIG. 2. VCPko is attenuated in wild-type but not C3/ mice. (A
and B) B6 (n  5) (A) or C3/ mice (n  4 for vv-VCPwt and n 
5 for vv-VCPko) (B) were infected with 2  104 vv-VCPwt or vv-
VCPko. Lesion sizes were measured over time. The differences in
lesion sizes between vv-VCPwt and vv-VCPko were statistically signif-
icant on days 6 to 12 (P	 0.01). (C and D) Representative lesions from
B6 (C) and C3/ (D) mice are shown at day 10 after infection. , P
	 0.01 (paired Student’s t test).
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VCP limits accumulation of T cells at the site of infection.
Control of viral replication in mice infected with vv-VCPko
coincides temporally with activation of adaptive immune re-
sponses. Although primary VACV infection can be cleared by
antibody alone, CD8 T cells can mediate protection and are
essential for controlling VACV infection in the absence of
antibody (1, 60). Because complement has been shown to affect
CD4 and CD8 T cell responses to several viruses (10, 23, 24,
37, 50), we compared numbers of T cells in the ears of mice
infected with vv-VCPwt versus vv-VCPko (Fig. 4). Following
intradermal infection with VACV, T cells are recruited to the
site of infection by day 7 postinfection, and these responses
peak at day 10 (22). To determine if VCP affected T cell
responses at the site of infection, we used flow cytometry to
examine accumulation of T cells in the ear on day 7 and day 10
after infection with vv-VCPko or vv-VCPwt. Infection with
vv-VCPko was associated with increases in total numbers of
cells (Fig. 4A) and in total numbers of CD3 cells (Fig. 4B) on
both day 7 and day 10 after infection. On day 7 postinfection,
vv-VCPko-infected mice had a 5-fold increase in CD4 T cells
(Fig. 4C) and a 4-fold increase in CD8 T cells (Fig. 4D) in the
ear. On day 10 after infection, mice infected with vv-VCPko
had 2-fold increases in both CD4 and CD8 T cells (Fig. 4C
and D). This finding demonstrates that in the absence of VCP,
total numbers of CD4 and CD8 T cells are increased. Im-
portantly, increased numbers of T cells at the site of vv-VCPko
infection also coincided with decreases in viral titers in the ears
of mice infected with this virus, suggesting that enhanced T cell
accumulation may contribute to better control of viral replica-
tion. In contrast to B6 mice, C3/ mice infected with vv-
VCPwt or vv-VCPko had similar numbers of CD4 and CD8
T cells in the ear at day 10 postinfection (Fig. 4). Taken to-
gether, these results show that VCP limits accumulation of
CD4 and CD8 T cells at the site of infection in a comple-
ment-dependent manner.
Expression of VCP does not affect T cell priming or expan-
sion. Complement is necessary for optimal T cell priming and
expansion following infection with several viruses, including
influenza virus (24), WNV (37), and LCMV (10). Thus, it is
possible that the enhanced T cell response observed in the ear
following infection with vv-VCPko is due to greater T cell
expansion in the lymph node. To address this possibility, we
used MHC class I tetramers specific for the VACV immuno-
dominant peptide B820–27 (51) to monitor the antigen-specific
T cell responses in the draining lymph nodes of mice infected
with vv-VCPwt or vv-VCPko. We found no differences in the
percentages or total numbers of B8-specific CD8 T cells at
day 5 (Fig. 5A). On day 7, we observed only a small difference
in frequency but not in total number of tetramer-positive
(tet) CD8 T cells at day 7 (Fig. 5A and B). Since day 7
represents the peak of the anti-VACV T cell response in the
draining LN, this result suggests that VCP has minimal effects
on T cell priming and expansion. On day 10 postinfection, we
found that the draining LN of mice infected with vv-VCPko
had significantly lower percentages but only modestly reduced
total numbers of B8-specific CD8 T cells than vv-VCPwt-
infected mice (Fig. 5A and B). To confirm this result, we also
restimulated T cells from infected mice with B820–27 and ex-
amined production of IFN- by CD8 T cells on day 10 after
infection. We found that mice infected with vv-VCPko also had
modestly reduced frequencies and total numbers of IFN--
positive CD8 T cells in the draining lymph nodes (Fig. 5C and
D). Thus, mice infected with vv-VCPko have increased num-
bers of CD8 T cells at the site of infection and slightly re-
duced numbers of antigen-specific CD8 T cells in the drain-
ing LN. It is possible that this finding may reflect differences in
FIG. 3. Kinetics of viral titers in the ear. Ears from B6 or C3/
mice infected with vv-VCPwt or vv-VCPko were harvested at the
indicated time points, and virus titers were determined (n  8 ears/
virus/time point for B6 mice; n  6 for C3/ mice on day 4; n  8 for
C3/ mice on days 8 and 12). , P 	 0.01; , P 	 0.05. Data for B6
mice are representative of two independent experiments that included
three to four mice per group. Data for C3/ mice represent combined
data from two experiments that included two to four mice per group.
FIG. 4. Infection with vv-VCPko results in increased accumulation
of T cells at the site of infection. Ears from B6 mice (n 4 mice/group)
or C3/ mice (n  3 mice/group for vv-VCPwt and 4 mice/group for
vv-VCPko) infected with vv-VCPko or vv-VCPwt were harvested and
cells isolated. Right and left ears from individual mice were pooled, but
mice were analyzed separately. Viable cells were identified by trypan
blue exclusion and counted on a hemacytometer (total cells, shown in
panel A). Cells were stained for viability and T cell markers as de-
scribed in Materials and Methods, and the frequencies of CD3,
CD4, and CD8 cells were determined using flow cytometry. Average
numbers of total (A), CD3 (B), CD4 (C), and CD8 (D) cells are
shown. Error bars represent standard errors of the means. , P 	
0.01; , P 	 0.05 (Student’s t test). Results are representative of four
independent experiments with B6 mice and three independent exper-
iments with C3/ mice.
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T cell trafficking or retention of T cells at the site of infection
in mice infected with vv-VCPko. The modest differences ob-
served in the CD8 T cell responses in the dLN suggest that
VCP does not dramatically impact T cell priming. Defining the
precise mechanism by which VCP limits T cell responses will
require further investigation.
Infection with vv-VCPko induces better neutralizing Ab re-
sponses. Ab responses are important for clearance of primary
VACV infection (1, 60). Further, complement activation is
important for the development of optimal IgM and IgG anti-
body responses to several viruses (7, 38, 44). Therefore, we
examined the effect of VCP expression on the development
of anti-VACV IgM and IgG Ab responses by using a VACV-
specific ELISA to measure levels of anti-VACV Abs follow-
ing infection of B6 mice with vv-VCPwt and vv-VCPko.
Infection with vv-VCPko resulted in significantly increased
titers for both the IgM and IgG Ab responses on days 10 and
13 after infection compared to infection with vv-VCPwt
(Fig. 6A and B).
To demonstrate the biological importance of this difference
in IgM and IgG, we measured anti-VACV neutralizing Ab
(nAb) responses by determining the ability of sera from in-
fected mice to neutralize virus in an in vitro plaque reduction
assay. Sera from B6 mice infected with vv-VCPko or vv-VCPwt
had similar neutralization abilities at day 5 postinfection (Fig.
6C). However, on day 7 and day 10, sera from mice infected
with vv-VCPko more effectively neutralized virus. By day 13,
serum from mice infected with either vv-VCPwt or vv-VCPko
was able to neutralize virus almost completely (Fig. 6C). The
kinetics that we observed for nAb responses are consistent with
a recent study examining early IgM and IgG responses in
VACV-immunized mice (41). Although we did not observe
differences in the levels of Ab by ELISA at times prior to day
10 (Fig. 6A and B), serum from mice infected with vv-VCPko
was better able to neutralize virus on day 7 after infection (Fig.
6C). Thus, in addition to an early dampening of the magnitude
of the anti-VACV Ab response, it is possible that VCP affects
other aspects of the Ab response, such as Ab affinity. Impor-
tantly, the increase in nAb in sera from vv-VCPko-infected
mice on day 7 coincided with the decrease in viral titer we saw
in these mice (Fig. 3A), suggesting that enhanced nAb re-
sponses may contribute to control of viral replication. These
differences in neutralization were not seen with samples taken
from C3/ mice. Sera from C3/ mice infected with vv-
VCPwt or vv-VCPko had equivalent abilities to neutralize virus
at all time points tested (Fig. 6C), demonstrating that the
enhanced nAb response in B6 mice infected with vv-VCPko is
dependent on complement.
CD8 T cells and CD4 T cells contribute to attenuation of
vv-VCPko. The data presented so far suggest that expression
of VCP by vv-VCPwt limits recruitment of T cells to the site
of infection and dampens nAb responses. Since Th-depen-
dent Ab responses and CD8 T cells can individually me-
diate protection against VACV (1, 60), the ability of VCP to
modulate both of these responses may contribute to the
attenuation of vv-VCPko. The Ab response to poxviruses is
almost completely Th dependent (12, 47, 60). Therefore,
depleting CD4 T cells also eliminates Ab responses (12, 47,
60). To address the contributions of enhanced nAb and
CD8 T cell responses during infection with vv-VCPko, we
depleted mice of CD8 and CD4 T cells individually or
together and examined lesion sizes (Fig. 7A and B) and viral
titers (Fig. 7C) following infection with vv-VCPwt or vv-
VCPko. When mice were depleted of CD4 or CD8 T cells
FIG. 5. VCP does not alter T cell priming in the draining lymph node. Cells were isolated from dLN of mice infected with either vv-VCPwt
or vv-VCPko on the indicated days after infection and stained directly ex vivo with VACV tetramer specific for B820–27. (A) FACS plots gated on
CD8 T cells display representative data from day 10 postinfection, showing differences in the frequencies of tet CD8 T cells. Numbers are the
percentages of tet, CD44 CD8 T cells and are representative of two experiments (three to four mice per group). (B) Plots gated on CD8 T
cells and percentages representing the frequencies of IFN- CD8 T cells. The graphs display the frequencies and total numbers of tet CD8
T cells on the indicated days. (C) FACS plots gated on CD8 T cells, showing frequencies of IFN- CD8 T cells in dLN on day 10 postinfection.
(D) Graphs displaying the average frequencies and total numbers of IFN- CD8 T cells in the dLN on day 10 postinfection. Data are
representative of four experiments with three to five mice per group.
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individually, infection with vv-VCPko was still associated
with formation of smaller lesions. However, when CD4 and
CD8 T cells were depleted together, vv-VCPko-infected
mice developed lesions that were the same size as in mice
infected with vv-VCPwt (Fig. 7A and B) and had similar
viral titers in the ear on day 8 postinfection (Fig. 7C). As has
been demonstrated in several previous studies (12, 47, 60),
depletion of CD4 T cells was associated with an absence of
VACV-specific Ab responses (data not shown).
Taken together, these data show that depletion of both
CD4 and CD8 T cells restores the virulence of vv-VCPko,
and they strongly suggest that VCP contributes to pathogenesis
by limiting both Ab and T cell responses.
Immunization with vv-VCPko provides enhanced protection
against challenge. Vaccination with VACV provides protec-
tion against subsequent infection with antigenically related
poxviruses, including variola virus (VARV), monkeypox virus
(MPXV), and ectromelia virus (ECTV) (13). Protection
against secondary poxvirus infection is primarily mediated by
Abs, but CD8 T cell responses also contribute to control of
viral replication and dissemination (1, 8, 11, 12, 33, 34, 60, 61).
FIG. 6. Infection with vv-VCPko results in increased neutralizing
Ab responses. The amount of VACV-specific IgM (A) or IgG (B) in
sera from wild-type B6 mice infected with vv-VCPwt or vv-VCPko was
determined by ELISA with VACV-infected cell lysate. Graphs repre-
sent average values 
 standard errors of the means for heat-inacti-
vated sera from individual mice (n  4 mice/virus/time point) at the
indicated dilutions. (C) The ability of sera to neutralize MV was tested
by using a standard plaque reduction neutralization assay. Wild-type
B6 or C3/ mice infected with vv-VCPwt or vv-VCPko were bled on
the indicated days. Heat-inactivated serum from individual mice was
incubated with MV for 2 h, and virus titers were determined on BSC-1
cells. Graphs represent percentages of infectivity remaining after in-
cubation with serum, 
 standard errors of the means. Values for
infected mice are normalized to heat-inactivated serum pooled from
eight naïve mice and were analyzed in triplicate. Statistical significance
was determined using a paired Student’s t test. , P 	 0.05. Results are
representative of two similar experiments.
FIG. 7. Depletion of CD4 and CD8 T cells together, but not
individually, restores virulence of vv-VCPko. Mice were depleted of
CD4 and or CD8 T cells prior to infection with vv-VCPwt or
vv-VCPko, and lesion sizes were monitored. (A) Average lesion sizes
on day 8 postinfection 
 standard errors of the means. (B) Photomi-
crographs showing lesions that represent the median lesion sizes of
each group. (C) Average viral titers in the ear on day 8 postinfection

standard errors of the means (n  4 mice/group). , P 	 0.05. Results
are representative of two independent experiments each testing 4
mice/group.
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Since primary infection with vv-VCPko induced stronger Ab
and T cell responses, we hypothesized that it may also provide
better protection against lethal challenge when used to vacci-
nate mice. To test this, we immunized mice by the intradermal
route by injecting a total of 4  104 PFU of vv-VCPwt or
vv-VCPko into the ear pinnae. Immunized mice were chal-
lenged 30 days later, and weight loss was monitored. Mice that
had been immunized with vv-VCPko lost less weight and re-
covered more rapidly than mice immunized with vv-VCPwt
(Fig. 8). This suggests that immunization with vv-VCPko in-
creases protective immunity. Since vv-VCPko is also attenu-
ated during primary infection, viruses that do not express VCP
may serve as safer, more effective vaccine vectors.
DISCUSSION
VCP has previously been shown to increase VACV virulence
in intradermal models of VACV infection in rabbits and
guinea pigs (20). Our data recapitulate this finding but also
extend our understanding of VCP’s role in pathogenesis. We
show here that VCP limits protective adaptive immune re-
sponses to VACV by dampening nAb responses and limiting
accumulation of CD4 and CD8 T cells at the site of infec-
tion, resulting in increased viral replication. Importantly, the
use of C3/ mice showed that these effects of VCP are de-
pendent on an intact complement system, and thus they dem-
onstrate for the first time that pathogen-encoded complement
regulatory proteins can modulate adaptive immunity in a com-
plement-dependent manner.
Complement activation can contribute to direct and indirect
control of viral replication by opsonizing and/or lysing viral
particles or infected cells and by enhancing adaptive immune
responses. To begin to understand how VCP contributes to
virulence in vivo, we first examined the kinetics of viral repli-
cation. We observed that mice infected with vv-VCPko con-
trolled viral replication better than mice infected with vv-
VCPwt, but only at the later time points examined (days 8 and
12); viral titers were similar at day 4 (Fig. 2) and day 6 (data not
shown). The observation that vv-VCPko-infected mice exhib-
ited better viral control only late in infection suggests that VCP
contributes to pathogenesis by limiting adaptive immune re-
sponses to VACV. Indeed, we found that vv-VCPko-infected
mice had increased numbers of CD4 and CD8 T cells at the
site of infection (Fig. 3) and enhanced nAb responses (Fig. 4)
by day 7 postinfection. These results are consistent with several
viral infection models that have demonstrated that comple-
ment contributes to control of viral infection by inducing adap-
tive immune responses (10, 23, 24, 37, 38, 44, 50, 55, 56).
A recent study using ECTV to examine the role of comple-
ment in poxvirus infection showed that infection of C3/ mice
with ECTV resulted in elevated viral titers as early as day 2 in
the spleen and day 4 in the liver and the blood (40). In contrast
to that study, we found that at such early time points there was
no difference in viral titers in B6 or C3/ mice infected with
vv-VCPwt or vv-VCPko. However, one key difference in the
ECTV model is that this mouse-specific virus replicates exten-
sively in the mouse and spreads to the draining lymph nodes
and then through the blood to seed the liver and the spleen. In
contrast to ECTV, after intradermal inoculation, VACV
spreads relatively poorly in mice and remains localized to the
dermis (52). The blood contains very high levels of comple-
ment, leading to rapid opsonization of pathogens and enhance-
ment of complement receptor-mediated recognition and
phagocytosis (18). Thus, while complement limits early viral
dissemination via the blood in a systemic model of poxvirus
infection, our results indicate that it may not contribute to
initial control of localized VACV replication in the intrader-
mal model.
Although we show that VCP limits accumulation of T cells at
the site of infection in a complement-dependent manner, our
studies do not define the mechanism by which VCP affects T
cell responses. However, our findings are consistent with sev-
eral models of viral infection that have demonstrated that
C3/ mice have decreased numbers of T cells at sites of viral
infection, including the lungs of mice infected with influenza
virus (24) and the brains of mice infected with WNV (37). In
both the influenza virus and WNV models, defects in T cell
accumulation at sites of infection correlate with reduced T cell
priming and/or proliferation (24, 37). However, when we ex-
amined VACV-specific T cell responses in the dLN of infected
mice, we found only very slight differences in the CD8 T cell
responses to vv-VCPko and vv-VCPwt at day 5 and day 7. This
result suggests that complement may not contribute to T cell
priming and expansion in our infection model. We did observe
a difference in CD8 T cell responses on day 10 postinfection; at
this time point, mice infected with vv-VCPko had fewer tet
and IFN- CD8 T cells in the dLN. It is possible that VCP
alters T cell trafficking to or retention at the site of infection.
Although complement has been shown to affect T cell priming
in numerous models, it can also influence T cell responses in
other ways. For instance, C3 deficiency has been shown to alter
lymphocyte survival (49). Furthermore, inhibiting the C5a re-
ceptor can limit recruitment of T cells to the lungs of mice
infected with influenza virus without affecting T cell priming
(23). Thus, there are multiple alternative mechanisms by which
VCP may limit CD8 T cell responses during VACV infection.
One possibility is that VCP suppresses local complement acti-
vation, and by doing so dampens inflammatory responses at the
FIG. 8. Increased protection from lethal challenge in mice vacci-
nated with vv-VCPko. Mice were immunized in the ear pinna with 2 
104 PFU of vv-VCPwt, vv-VCPko, or saline (n  5 mice/group). Thirty
days after immunization mice were challenged i.n. with 1  107 PFU
of strain WR. Results show average weight loss following challenge 

the standard errors of the means and are representative of two exper-
iments. , P 	 0.05.
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site of infection, leading to decreased infiltration of leukocytes.
This possibility is consistent with a previous study showing that
the cowpox ortholog of VCP, inflammation modulatory pro-
tein (IMP), reduces recruitment of inflammatory cells to the
site of infection (39). Furthermore, mammalian complement
regulatory proteins have also been shown to limit accumulation
of leukocytes at sites of inflammation. For instance, adminis-
tering soluble complement receptor 1 (sCR1) to mice has been
shown to limit T cell-mediated delayed-type hypersensitivity
responses in skin by limiting the influx of T cells to the site of
antigen challenge (53, 54).
Recent efforts to better define the antiviral functions of Abs
during poxvirus infection have revealed an important role for
complement in Ab-mediated protection (2, 3). Benhnia et al.
showed that monoclonal Abs (MAbs) specific for the EV pro-
tein B5 that are able to initiate complement-mediated lysis of
infected cells and complement-dependent neutralization of
EV particles in vitro provide better protection against VACV
challenge following passive immunization (2, 3). Furthermore,
the enhanced protection provided by these MAbs in vivo was
reduced when mice that had been passively immunized were
depleted of complement prior to challenge, demonstrating that
enhanced protection depended on the ability of MAbs to ac-
tivate complement (3). Our data demonstrate that VCP limits
the early nAb antibody response, but it is also likely that VCP
reduces complement-mediated neutralization by nAbs that are
produced. The ability of VCP to dampen the magnitude of the
nAb response and limit the effector functions of Ab that are
produced may both contribute to VCP’s role in pathogenesis.
These findings may explain why viral titers in C3/ mice
remain high on day 12. T cell accumulation in C3/ mice is
reduced but is not absent (Fig. 3). C3/ mice also develop
nAb responses, although with somewhat delayed kinetics (Fig.
4). Thus, it is possible that the combination of decreased T cell
accumulation, reduced nAb production, and the inability of
these Abs to mediate complement-dependent neutralization
and lysis due to the absence of C3 may contribute to an inabil-
ity of these mice to control viral replication.
VCP primarily prevents complement-mediated neutraliza-
tion of Ab-sensitized virions in vitro (19, 21). The observation
that mice infected with vv-VCPko have lower viral titers only at
later times during infection may also indicate that VCP limits
VACV neutralization after induction of virus-specific IgM and
IgG. It was recently shown that natural IgM Abs can bind to
poxviruses and initiate the classical pathway in the absence of
specific IgM and IgG (40). However, since VCP is not present
until infected cells begin secreting proteins, it is possible that
early in infection there is not enough VCP to prevent comple-
ment-enhanced neutralization by natural IgM, rendering vv-
VCPwt and vv-VCPko equally susceptible to complement-me-
diated neutralization early in infection.
Protection against primary VACV infection is dependent on
Ab responses but can also be mediated by CD8 T cells if
humoral responses are absent (1, 60). To determine whether
enhanced CD8 T cell responses or Ab responses contributed
to the attenuation of vv-VCPko, we depleted CD4 and CD8
T cells (Fig. 5). CD4 T cell help is critical for induction of
VACV-specific Abs, and depleting these cells abrogates IgM
and IgG Ab responses to the virus (1, 47, 60). When either
CD4 or CD8 T cells were depleted individually, vv-VCPko
still formed smaller lesions and had reduced viral titers. How-
ever, when both of these subsets were depleted together, vv-
VCPko formed lesions that were the same size as those formed
by vv-VCPwt and replicated to a similar level (Fig. 5). Based on
our findings, we propose that when CD8 T cells are depleted,
enhanced nAb responses induced by infection with vv-VCPko
are sufficient to reduce viral titers. Similarly, when only CD4
T cells are depleted, which also abrogates virus-specific Ab
responses, increased accumulation of CD8 T cells at the site
of vv-VCPko infection reduces viral titers. This model is con-
sistent with several studies that have shown that protection
against VACV is primarily Ab mediated but can be mediated
by CD8 T cells if Ab is absent (1, 60). This model also implies
that the ability of VCP to modulate CD8 T cell responses
without also dampening Ab responses would not increase
pathogenesis, since loss of either Ab or CD8 T cells alone did
not restore virulence of vv-VCPko (Fig. 5). An important ca-
veat of our study is that we have not directly addressed the role
of Ab; in our experiments loss of Ab is secondary to the
absence of CD4 T cells. Providing help to B cells is the
primary function attributed to CD4 T cells during VACV
infection, since mice lacking CD4 T cells have the same
phenotype as B cell-deficient mice (60). However, CD4 T
cells have additional functions beyond providing B cell help,
including production of proinflammatory cytokines. It is pres-
ently unclear whether CD4 T cells have direct antiviral activ-
ity during VACV infection, although it is possible that they
represent an important source of proinflammatory cytokines
during intradermal infection. Thus, it may be possible that
depletion of both CD4 and CD8 T cells eliminates two
major sources of inflammatory cytokines, leading to increased
viral replication.
Following i.p. or i.n. infection, VACV can be cleared by
either Th-dependent Ab responses or CD8 T cells indepen-
dently (1, 60). Our data suggest that during an intradermal
infection, the decrease in viral titers in vv-VCPko-infected
mice at day 8 is due to enhanced nAb and/or CD8 T cells.
Furthermore, these responses can control viral replication in-
dependently, since elimination of either one alone is insuffi-
cient to restore virulence of vv-VCPko (Fig. 5). This suggests
that i.d. VACV infection is controlled by similar mechanisms
as are i.p. and i.n. infections.
Interestingly, although depletion of CD4 and CD8 T cells
restored virulence of vv-VCPko, depletion of both of these
subsets did not further increase the virulence of vv-VCPko and
vv-VCPwt at day 8 postinfection; lesions sizes and viral titers in
mice depleted of CD4 and CD8 T cells were similar to those
in intact mice infected with vv-VCPwt (Fig. 5). Several studies
have shown that the amount of VACV replication that can
occur in skin is limited. This has been consistently reported for
i.d. infection in the ear pinna (52) and in flank skin (28). Thus,
the level of viral replication observed for vv-VCPwt in unde-
pleted mice may represent the maximum level of viral replica-
tion that can occur in skin. This concept is also consistent with
the observation that viral replication is sustained in C3/
mice as late as day 12 after infection but is not associated with
an increase in viral titer beyond levels observed at the peak of
viral replication (Fig. 2).
In addition to its effects on the adaptive immune response to
primary VACV infection, we have also shown that vaccination
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with vv-VCPko provides better protection against lethal
VACV challenge than vaccination with vv-VCPwt. While it
may seem counterintuitive that infection with vv-VCPko,
which results in lower viral replication, would provide better
vaccine-induced immunity, our data suggest that increased
complement activation due to the absence of VCP enhances
Ab and T cell responses, resulting in better protection. Defin-
ing the precise mechanisms by which vaccination with vv-
VCPko enhances protective immunity will be an interesting
area of future investigation.
The ability of VCP to limit adaptive immune responses to
VACV may have implications for infection with other or-
thopoxviruses that cause human disease. Both VARV and
MPXV express orthologs of VCP that have been shown to
regulate complement activation in vitro (30–32, 46, 48). The
MPXV homolog of VCP (known as MoPICE) is thought to
contribute to virulence because it is expressed by the more
virulent Central African strain of this virus but is not found in
the less pathogenic West African strain (6, 29). Additionally,
complement-deficient mice succumb to infection with ECTV
(40), demonstrating the importance of complement in protec-
tion against pathogenic poxvirus infection. In light of our re-
sults, it would be interesting to determine whether the MPXV
and ECTV VCP orthologs (MoPICE and EMICE, respec-
tively) also affect adaptive immune responses to these viruses.
VACV serves as a useful model for assessing the function of
poxvirus immunomodulatory proteins in vivo, and the intrad-
ermal model of infection mimics human intradermal vaccina-
tion. However, it should be noted that VACV is not a natural
mouse pathogen and causes milder disease in mice than
ECTV, which causes lethal smallpox-like disease in mice.
Therefore, it will be particularly interesting to examine the
effects of deletion of the ECTV complement regulatory pro-
tein on pathogenesis in the mousepox infection model.
Our findings are consistent with several studies that have
demonstrated that complement activation contributes to con-
trol of viral infection by modulating T cell and Ab responses.
However, none of these studies addressed the ability of patho-
gen-encoded complement regulatory proteins to modulate
adaptive immune responses during infection. We have shown
that VCP contributes to virulence in a complement-dependent
manner and that expression of this protein by VACV decreases
T cell accumulation at the site of infection and dampens neu-
tralizing Ab responses.
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